Woburn, MA-based biotech Pathogenetix, formerly known as U.S. Genomics, has raised $1.3 million in equity-based funding, and $900,000 of a planned $1.2 million debt-based offering, according to filings with the SEC. U.S. Genomics developed biodefense and diagnostic technologies, and raised $4.5 million in private equity funding from Becton, Dickinson & Co in 2008, as part of a strategic partnership for pursuing diagnostics for infectious diseases. Pathogenetix has not yet returned a call seeking comment on the newest funding and the company name change.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
